Justin Zelin, an analyst from BTIG, reiterated the Buy rating on ProKidney (PROK – Research Report). The associated price target is $6.00.

The REACT trial was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, phase 3 study conducted at 74 sites in 15 countries across North America and Europe.

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the U.S.-based PROACT 1. But the biotech scrapped PROACT 2 in September 2024 after ...

Shares in Idorsia Ltd. plummeted by around 14% Feb. 6 as the company announced that its phase III REACT trial investigating the use of Pivlaz (clazosentan) failed to reach the primary endpoint in ...

Between May 2010 and July 2014, a total of 700 patients were enrolled in the trial at 22 centers in Japan and were randomly assigned to the AF group (N=349) or the CF group (N=351).